Dr. Jonasch on the Potential of Immunotherapy for Sarcomatoid RCC

Eric Jonasch, MD
Published: Thursday, Jun 22, 2017



Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Sarcomatoid RCC is a difficult area to treat from an efficacy standpoint, explains Jonasch. Emerging data suggest that immuno-oncology agents might be useful for this patient population.

There are published data demonstrating that PD-L1 expression is higher with sarcomatoid RCC and raises the hypothesis that targeting PD-1/PD-L1 might be beneficial, states Jonasch.
 


Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Sarcomatoid RCC is a difficult area to treat from an efficacy standpoint, explains Jonasch. Emerging data suggest that immuno-oncology agents might be useful for this patient population.

There are published data demonstrating that PD-L1 expression is higher with sarcomatoid RCC and raises the hypothesis that targeting PD-1/PD-L1 might be beneficial, states Jonasch.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x